Table 3.
Preoperative and operative characteristics of the 148 least (categories 1 and 2) and 54 most (categories 4 and 5) socioeconomically deprived patients undergoing liver resection for colorectal liver metastases
| Least deprived patients |
Most deprived patients |
|||
|---|---|---|---|---|
| Categories 1 + 2 (n = 148) | Categories 4 + 5 (n = 54) | P-value | ||
| Age, years, median (range) | 67 (34–88) | 67 (33–90) | 0.562 | |
| Gender, n (%) | Female | 56 (37.8%) | 23 (42.6%) | 0.625 |
| Male | 92 (62.2%) | 31 (57.4%) | ||
| T stage of primary, n (%) | 0 | 2 (1.4%) | 0 | 0.060 |
| 1 | 4 (2.7%) | 1 (1.9%) | ||
| 2 | 12 (8.1%) | 2 (3.7%) | ||
| 3 | 71 (48.0%) | 39 (72.2%) | ||
| 4 | 52 (35.1%) | 11 (20.4%) | ||
| Unavailable | 7 (4.7%) | 1 (1.9%) | ||
| N stage of primary, n (%) | 0 | 64 (43.2%) | 24 (44.4%) | 0.781 |
| 1 | 50 (33.7%) | 16 (29.6%) | ||
| 2 | 30 (20.3%) | 13 (24.1%) | ||
| Unavailable | 4 (2.7%) | 1 (1.9%) | ||
| Site of primary, n (%) | Colonic | 77 (52.0%) | 29 (53.7%) | 0.874 |
| Rectal | 71 (48.0%) | 25 (46.3%) | ||
| Timing | Synchronous | 71 (48.0%) | 21 (38.9%) | 0.268 |
| Metachronous | 77 (52.0%) | 33 (61.1%) | ||
| Preoperative MRI, n (%) | Yes | 83 (56.1%) | 29 (53.7%) | 0.873 |
| No | 65 (43.9%) | 25 (46.3%) | ||
| Preoperative PET, n (%) | Yes | 111 (75.0%) | 25 (46.3%) | <0.001 |
| No | 37 (25.0%) | 29 (53.7%) | ||
| Preoperative liver-directed chemotherapy, n (%) | Yes | 77 (52.0%) | 25 (46.3%) | 0.526 |
| No | 71 (48.0%) | 29 (53.7%) | ||
| Preoperative diabetes, n (%) | Yes | 16 (10.8%) | 3 (5.6%) | 0.413 |
| No | 132 (89.2%) | 51 (94.4%) | ||
| BMI, kg/m2, median (range) | 27 (17–39) | 27 (19–54) | 0.859 | |
| ASA class, n (%) | 1 | 16 (10.8%) | 1 (1.9%) | 0.030 |
| 2 | 104 (70.3%) | 36 (66.7%) | ||
| 3 | 28 (18.9%) | 17 (31.5%) | ||
| Neutrophil : lymphocyte ratio, median (range) | 2.38 (0.50–10.10) | 2.85 (0.94–17.25) | 0.161 | |
| Preoperative albumin, g/dl, median (range) | 44 (29–51) | 43 (34–51) | 0.102 | |
| POSSUM physiological score, median (range) | 16 (12–32) | 17 (13–30) | 0.720 | |
| RFA included, n (%) | Yes | 11 (7.4%) | 4 (7.4%) | 1.000 |
| No | 137 (92.6%) | 50 (92.6%) | ||
| Wedge resection included, n (%) | Yes | 68 (45.9%) | 21 (38.9%) | 0.425 |
| No | 80 (54.1%) | 33 (61.1%) | ||
| Number of segments resected, median (range) | 4 (1–6) | 3 (1–6) | 0.617 | |
| Repeat operation, n (%) | Yes | 15 (10.1%) | 4 (7.4%) | 0.786 |
| No | 133 (89.9%) | 50 (92.6%) | ||
| Curative resection, n (%) | Yes | 136 (91.9%) | 53 (98.1%) | 0.191 |
| No | 12 (8.1%) | 1 (1.9%) | ||
| Number of liver metastases, median (range) | 2 (1–10) | 1 (1–8) | 0.317 | |
| Maximum diameter of metastases, mm, median (range) | 30 (3–120) | 35 (5–120) | 0.063 | |
| Resection margin, n (%) | R0 | 115 (77.7%) | 44 (81.5%) | 0.698 |
| R1 | 33 (22.3%) | 10 (18.5%) | ||
MRI, magnetic resonance imaging;
PET, positron emission tomography;
BMI, body mass index;
ASA, American Society of Anesthesiologists;
RFA, radiofrequency ablation.